BackRegenerative Medical Technology Group Overview

Regenerative Medical Technology Group EBIT

Regenerative Medical Technology Group's EBIT is $1.6M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$565.98K
↑ 326.02% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

$1.63M
↑ 468.68% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Regenerative Medical Technology Group (RMTG) FAQ

The latest EBIT for RMTG is $1.6M as of June 2026. That compares with $290K in the prior-year period — up 468.7% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Regenerative Medical Technology Group's historical trend and sector peers before judging valuation or financial health.

Over the past year, RMTG's EBIT moved from $290K to $1.6M — a 468.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Regenerative Medical Technology Group's operating scale or balance-sheet position.

Against Healthcare companies, RMTG currently prints $1.6M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Regenerative Medical Technology Group's growth, margins, and balance sheet.

A EBIT figure of $1.6M for RMTG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting RMTG's EBIT ($1.6M), review year-over-year change from $290K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.